Overview

  • Product nameAnti-KRIT1 antibody
    See all KRIT1 primary antibodies
  • Description
    Mouse monoclonal to KRIT1
  • Tested applicationsSuitable for: ELISAmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Mouse, Rat, Cow
  • Immunogen

    Recombinant fragment: AAFFTGQIFT KASPSNHKVI PVYVGVNIKG LHLLNMETKA LLISLKYGCF MWQLGDTDTC FQIHSMENKM SFIVHTKQAG LVVKLLMKLN GQLMPTERNS , corresponding to amino acids 637-736 of Human KRIT1 with a 26kDa tag

  • Positive control
    • KRIT1 transfected 293T cell lysate

Properties

Applications

Our Abpromise guarantee covers the use of ab54889 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ELISA Use at an assay dependent dilution. Detection limit is approximately 0.03ng/ml as a capture antibody when used against the immunogen.

Target

  • FunctionNegative regulator of angiogenesis. Inhibits endothelial proliferation, apoptosis, migration, lumen formation and sprouting angiogenesis in primary endothelial cells. Promotes AKT phosphorylation in a NOTCH-dependent and independent manner, and inhibits EKR1/2 phosphorylation indirectly through activation of the DELTA-NOTCH cascade. Acts in concert with CDH5 to establish and maintain correct endothelial cell polarity and vascular lumen and these effects are mediated by recruitment and activation of the Par polarity complex and RAP1B. Required for the localization of phosphorylated PRKCZ, PARD3, TIAM1 and RAP1B to the cell junction. Plays an important role in the maintenance of the intracellular reactive oxygen species (ROS) homeostasis to prevent oxidative cellular damage. Regulates the homeostasis of intracellular ROS through an antioxidant pathway involving FOXO1 and SOD2. Facilitates the down-regulation of cyclin D1 levels required for cell transition from proliferative growth to quiescence by preventing the accumulation of intracellular ROS through the modulation of FOXO1 and SOD2 levels.
  • Tissue specificityLow levels in brain. Very weak expression found in heart and muscle.
  • Involvement in diseaseDefects in KRIT1 are the cause of cerebral cavernous malformations type 1 (CCM1) [MIM:116860]. Cerebral cavernous malformations (CCMs) are congenital vascular anomalies of the central nervous system that can result in hemorrhagic stroke, seizures, recurrent headaches, and focal neurologic deficits. CCMs have an incidence of 0.1%-0.5% in the general population and usually present clinically during the 3rd to 5th decade of life. The lesions are characterized by grossly enlarged blood vessels consisting of a single layer of endothelium and without any intervening neural tissue, ranging in diameter from a few millimeters to several centimeters.
  • Sequence similaritiesContains 4 ANK repeats.
    Contains 1 FERM domain.
  • Cellular localizationMembrane. Cell junction. KRIT1 and CDH5 reciprocally regulate their localization to endothelial cell-cell junctions.
  • Information by UniProt
  • Database links
  • Alternative names
    • Ankyrin repeat containing protein Krit1 antibody
    • CAM antibody
    • CCM 1 antibody
    • CCM1 antibody
    • Cerebral cavernous malformations 1 antibody
    • Cerebral cavernous malformations 1 protein antibody
    • Krev interaction trapped 1 antibody
    • Krev interaction trapped protein 1 antibody
    • KRIT 1 antibody
    • KRIT1 ankyrin repeat containing antibody
    • KRIT1 antibody
    • KRIT1_HUMAN antibody
    see all

Anti-KRIT1 antibody images

  • Detection of immunogen (recombinant fragment) at the indicated concentrations using ab54889 at 0.03ng/ml.

References for Anti-KRIT1 antibody (ab54889)

ab54889 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab54889.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"